You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that it delivered 27,126 flagship Avise CTD tests, including Avise Lupus, during the recently completed quarter, a 13 percent year-over-year increase.
The combined company will have operations in California and Texas, and will provide onsite, rapid diagnostics with data analytics capabilities.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
The four kits are compatible with the i-Track automated analyzer for biotherapy monitoring, which received CE marking in late 2019.
The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
The firm has partnered with Leiden University Medical Center to study the use of its Immray platform to diagnose patients with rheumatoid arthritis.
The firm is adding data on patient risk for radiographic progression and cardiovascular events to the test, which was recently included in the ACR guidelines.
Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D.
The immunoassays are are indicated for the quantitative determination of IgM RF antibodies and the semi-quantitative determination of IgA RF antibodies.